Functionalized lipid-based drug delivery nanosystems for the treatment of human infectious diseases

Abstract

Infectious diseases are still public health problems. Microorganisms such as fungi, bacteria, viruses, and parasites are the main causing agents related to these diseases. In this context, the search for new effective strategies in prevention and/or treatment is considered essential, since current drugs often have side effects or end up, causing microbial resistance, making it a serious health problem. As an alternative to these limitations, nanotechnology has been widely used. The use of lipid-based drug delivery nanosystems (DDNs) has some advantages, such as biocompatibility, low toxicity, controlled release, the ability to carry both hydrophilic and lipophilic drugs, in addition to be easel scalable. Besides, as an improvement, studies involving the conjugation of signalling molecules on the surfaces of these nanocarriers can allow the target of certain tissues or cells. Thus, this review summarizes the performance of functionalized lipid-based DDNs for the treatment of infectious diseases caused by viruses, including SARS-CoV-2, bacteria, fungi, and parasites.

Keywords:

• Targeting
• nanotechnology
• drug delivery nanosystem
• infectious diseases
• functionalization

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This study was financed in part by the Coordenação de Aperfeiçoamento Pessoal de nível Superior, Brasil (CAPES), Finance Code 001 and Fundação de Amparo à Pesquisa do Estado de São Paulo – FAPESP (2019/10261-2) and (2019/26821-7).